The DOI matches its Crossref record; 138 of the 138 references it cites were found in a registry or an index.
Opportunities and challenges for human papillomavirus vaccination in cancer
Open accessAbstract
The discovery of genotype 16 as the prototype oncogenic human papillomavirus (HPV) initiated a quarter century of laboratory and epidemiological studies that demonstrated their necessary, but not sufficient, aetiological role in cervical and several other anogenital and oropharyngeal cancers. Early virus-induced immune deviation can lead to persistent subclinical infection that brings the risk of progression to cancer. Effective secondary prevention of cervical cancer through cytological and/or HPV screening depends on regular and widespread use in the general population, but coverage is inadequate in low-resource settings. The discovery that the major capsid antigen L1 could self-assemble into empty virus-like particles (VLPs) that are both highly immunogenic and protective led to the licensure of several prophylactic VLP-based HPV vaccines for the prevention of cervical cancer. The implementation of vaccination programmes in adolescent females is underway in many countries, but their impact critically depends on the population coverage and is improved by herd immunity. This Review considers how our expanding knowledge of the virology and immunology of HPV infection can be exploited to improve vaccine technologies and delivery of such preventive strategies to maximize reductions in HPV-associated disease, including incorporation of an HPV vaccine covering oncogenic types within a standard multitarget paediatric vaccine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Papillomaviruses and cancer: from basic studies to clinical application
zur Hausen, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc798 · Cited by 4,024
Classification of papillomaviruses
de Villiers, E.-M., Fauquet, C., Broker, T. R., Bernard, H.-U., & zur Hausen, H. (2004) · Virology · doi:10.1016/j.virol.2004.03.033 · Cited by 3,193
Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments
Bernard, H.-U., Burk, R. D., Chen, Z., van Doorslaer, K., Hausen, H. Z., & de Villiers, E.-M. (2010) · Virology · doi:10.1016/j.virol.2010.02.002 · Cited by 1,669
Global Burden of Human Papillomavirus and Related Diseases
Forman, D., de Martel, C., Lacey, C. J., Soerjomataram, I., Lortet-Tieulent, J., Bruni, L., Vignat, J., Ferlay, J., Bray, F., Plummer, M., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.07.055 · Cited by 1,642
Global burden of cancers attributable to infections in 2012: a synthetic analysis
Plummer, M., de Martel, C., Vignat, J., Ferlay, J., Bray, F., & Franceschi, S. (2016) · The Lancet Global Health · doi:10.1016/s2214-109x(16)30143-7 · Cited by 1,635
The Biology and Life-Cycle of Human Papillomaviruses
Doorbar, J., Quint, W., Banks, L., Bravo, I. G., Stoler, M., Broker, T. R., & Stanley, M. A. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.06.083 · Cited by 1,528
Integrated genomic and molecular characterization of cervical cancer
The Cancer Genome Atlas Research Network (2017) · Nature · doi:10.1038/nature21386 · Cited by 1,479
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
Joura, E. A., Giuliano, A. R., Iversen, O.-E., Bouchard, C., Mao, C., Mehlsen, J., Moreira, E. D., Ngan, Y., Petersen, L. K., Lazcano-Ponce, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405044 · Cited by 1,433
McCredie, M. R., Sharples, K. J., Paul, C., Baranyai, J., Medley, G., Jones, R. W., & Skegg, D. C. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70103-7 · Cited by 1,123
Kirnbauer, R., Booy, F., Cheng, N., Lowy, D. R., & Schiller, J. T. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.12180 · Cited by 1,110
Bruni, L., Diaz, M., Barrionuevo-Rosas, L., Herrero, R., Bray, F., Bosch, F. X., de Sanjosé, S., & Castellsagué, X. (2016) · The Lancet Global Health · doi:10.1016/s2214-109x(16)30099-7 · Cited by 824
A review of clinical trials of human papillomavirus prophylactic vaccines
Schiller, J. T., Castellsagué, X., & Garland, S. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.108 · Cited by 747
Vaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T., & Melief, C. J. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.16 · Cited by 709
Lehtinen, M., Paavonen, J., Wheeler, C. M., Jaisamrarn, U., Garland, S. M., Castellsagué, X., Skinner, S. R., Apter, D., Naud, P., Salmerón, J., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70286-8 · Cited by 704
Suzich, J. A., Ghim, S. J., Palmer-Hill, F. J., White, W. I., Tamura, J. K., Bell, J. A., Newsome, J. A., Jenson, A. B., & Schlegel, R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11553 · Cited by 668
Vaccine Adjuvants: from 1920 to 2015 and Beyond
Pasquale, A., Preiss, S., Silva, F., & Garçon, N. (2015) · Vaccines · doi:10.3390/vaccines3020320 · Cited by 648
Drolet, M., Bénard, É., Boily, M.-C., Ali, H., Baandrup, L., Bauer, H., Beddows, S., Brisson, J., Brotherton, J. M. L., Cummings, T., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)71073-4 · Cited by 642
Harro, C. D., Pang, Y.-Y. S., Roden, R. B. S., Hildesheim, A., Wang, Z., Reynolds, M. J., Mast, T. C., Robinson, R., Murphy, B. R., Karron, R. A., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.284 · Cited by 607
Self-citationCastellsague, X., & Munoz, N. (2003) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a003477 · Cited by 606
Breitburd, F., Kirnbauer, R., Hubbert, N. L., Nonnenmacher, B., Trin-Dinh-Desmarquet, C., Orth, G., Schiller, J. T., & Lowy, D. R. (1995) · Journal of Virology · doi:10.1128/jvi.69.6.3959-3963.1995 · Cited by 589
Jeon, S., Allen-Hoffmann, B. L., & Lambert, P. F. (1995) · Journal of Virology · doi:10.1128/jvi.69.5.2989-2997.1995 · Cited by 582
Kjaer, S. K., Frederiksen, K., Munk, C., & Iftner, T. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq356 · Cited by 579
Muñoz, N., Kjaer, S. K., Sigurdsson, K., Iversen, O.-E., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Brown, D. R., Koutsky, L. A., Tay, E. H., et al. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp534 · Cited by 566
Jeon, S., & Lambert, P. F. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1654 · Cited by 527
HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women
Gillison, M. L., Chaturvedi, A. K., & Lowy, D. R. (2008) · Cancer · doi:10.1002/cncr.23764 · Cited by 517
Roberts, J. N., Buck, C. B., Thompson, C. D., Kines, R., Bernardo, M., Choyke, P. L., Lowy, D. R., & Schiller, J. T. (2007) · Nature Medicine · doi:10.1038/nm1598 · Cited by 503
GIANNINI, S., HANON, E., MORIS, P., VANMECHELEN, M., MOREL, S., DESSY, F., FOURNEAU, M., COLAU, B., SUZICH, J., & LOSONKSY, G. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.06.005 · Cited by 496
Block, S. L., Nolan, T., Sattler, C., Barr, E., Giacoletti, K. E. D., Marchant, C. D., Castellsagué, X., Rusche, S. A., Lukac, S., Bryan, J. T., et al. (2006) · Pediatrics · doi:10.1542/peds.2006-0461 · Cited by 484
Medicine, N. L. O. (2008) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360280801989377 · Cited by 468
Olsson, S.-E., Villa, L. L., Costa, R. L. R., Petta, C. A., Andrade, R. P., Malm, C., Iversen, O.-E., Høye, J., Steinwall, M., Riis-Johannessen, G., et al. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.03.049 · Cited by 454
Updating the Natural History of Human Papillomavirus and Anogenital Cancers
Moscicki, A.-B., Schiffman, M., Burchell, A., Albero, G., Giuliano, A. R., Goodman, M. T., Kjaer, S. K., & Palefsky, J. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.05.089 · Cited by 413
Topical treatments for cutaneous warts
Kwok, C. S., Gibbs, S., Bennett, C., Holland, R., & Abbott, R. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001781.pub3 · Cited by 388
Richards, R. M., Lowy, D. R., Schiller, J. T., & Day, P. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508815103 · Cited by 375
Pastrana, D. V., Buck, C. B., Pang, Y.-Y. S., Thompson, C. D., Castle, P. E., FitzGerald, P. C., Krüger Kjaer, S., Lowy, D. R., & Schiller, J. T. (2004) · Virology · doi:10.1016/j.virol.2003.12.027 · Cited by 357
Arrangement of L2 within the Papillomavirus Capsid
Buck, C. B., Cheng, N., Thompson, C. D., Lowy, D. R., Steven, A. C., Schiller, J. T., & Trus, B. L. (2008) · Journal of Virology · doi:10.1128/jvi.02726-07 · Cited by 349
Establishment of human papillomavirus infection requires cell cycle progression
Pyeon, D., Pearce, S. M., Lank, S. M., Ahlquist, P., & Lambert, P. F. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000318 · Cited by 348
Mechanisms that determine plasma cell lifespan and the duration of humoral immunity
Amanna, I. J., & Slifka, M. K. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00912.x · Cited by 343
Heeren, A. M., Punt, S., Bleeker, M. C., Gaarenstroom, K. N., van der Velden, J., Kenter, G. G., de Gruijl, T. D., & Jordanova, E. S. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.64 · Cited by 310
de Jong, A., van Poelgeest, M. I. E., van der Hulst, J. M., Drijfhout, J. W., Fleuren, G. J., Melief, C. J. M., Kenter, G., Offringa, R., & van der Burg, S. H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0831 · Cited by 309
(2007) · PubMed Central · Cited by 309
Kreimer, A. R., Struyf, F., Del Rosario-Raymundo, M. R., Hildesheim, A., Skinner, S. R., Wacholder, S., Garland, S. M., Herrero, R., David, M.-P., & Wheeler, C. M. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00047-9 · Cited by 306
Kines, R. C., Thompson, C. D., Lowy, D. R., Schiller, J. T., & Day, P. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908502106 · Cited by 293
Gillison, M. L., Alemany, L., Snijders, P. J. F., Chaturvedi, A., Steinberg, B. M., Schwartz, S., & Castellsagué, X. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.05.070 · Cited by 289
Opalka, D., Lachman, C. E., MacMullen, S. A., Jansen, K. U., Smith, J. F., Chirmule, N., & Esser, M. T. (2003) · Clinical and Vaccine Immunology · doi:10.1128/cdli.10.1.108-115.2003 · Cited by 276
Roden, R. B., Greenstone, H. L., Kirnbauer, R., Booy, F. P., Jessie, J., Lowy, D. R., & Schiller, J. T. (1996) · Journal of Virology · doi:10.1128/jvi.70.9.5875-5883.1996 · Cited by 275
Self-citationVaccine impact: Benefits for human health
Doherty, M., Buchy, P., Standaert, B., Giaquinto, C., & Prado- Cohrs, D. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.10.025 · Cited by 272
Kavanagh, K., Pollock, K. G., Cuschieri, K., Palmer, T., Cameron, R. L., Watt, C., Bhatia, R., Moore, C., Cubie, H., Cruickshank, M., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30468-1 · Cited by 263
Papillomavirus-Like Particles Induce Acute Activation of Dendritic Cells
Lenz, P., Day, P. M., Pang, Y.-Y. S., Frye, S. A., Jensen, P. N., Lowy, D. R., & Schiller, J. T. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.9.5346 · Cited by 252
Daayana, S., Elkord, E., Winters, U., Pawlita, M., Roden, R., Stern, P. L., & Kitchener, H. C. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605611 · Cited by 252
Self-citationDay, P. M., Baker, C. C., Lowy, D. R., & Schiller, J. T. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404229101 · Cited by 245
Sankaranarayanan, R., Prabhu, P. R., Pawlita, M., Gheit, T., Bhatla, N., Muwonge, R., Nene, B. M., Esmy, P. O., Joshi, S., Poli, U. R. R., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00414-3 · Cited by 242
Human Papillomavirus, Human Immunodeficiency Virus and Immunosuppression
Denny, L. A., Franceschi, S., de Sanjosé, S., Heard, I., Moscicki, A. B., & Palefsky, J. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.06.045 · Cited by 237
A Protective and Broadly Cross-Neutralizing Epitope of Human Papillomavirus L2
Gambhira, R., Karanam, B., Jagu, S., Roberts, J. N., Buck, C. B., Bossis, I., Alphs, H., Culp, T., Christensen, N. D., & Roden, R. B. S. (2007) · Journal of Virology · doi:10.1128/jvi.00936-07 · Cited by 227
Self-citationEvasion of host immune defenses by human papillomavirus
Westrich, J. A., Warren, C. J., & Pyeon, D. (2017) · Virus Research · doi:10.1016/j.virusres.2016.11.023 · Cited by 219
Olsson, S.-E., Kjaer, S. K., Sigurdsson, K., Iversen, O.-E., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Brown, D. R., Koutsky, L. A., Hseon Tay, E., et al. (2009) · Human Vaccines · doi:10.4161/hv.5.10.9515 · Cited by 217
Human Papillomaviruses and Non-melanoma Skin Cancer
McLaughlin-Drubin, M. E. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.12.032 · Cited by 207
HPV-FASTER: broadening the scope for prevention of HPV-related cancer
Bosch, F. X., Robles, C., Díaz, M., Arbyn, M., Baussano, I., Clavel, C., Ronco, G., Dillner, J., Lehtinen, M., Petry, K.-U., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.146 · Cited by 206
Wheeler, C. M., Skinner, S. R., Del Rosario-Raymundo, M. R., Garland, S. M., Chatterjee, A., Lazcano-Ponce, E., Salmerón, J., McNeil, S., Stapleton, J. T., Bouchard, C., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30120-7 · Cited by 191
Genome-wide siRNA screen identifies the retromer as a cellular entry factor for human papillomavirus
Lipovsky, A., Popa, A., Pimienta, G., Wyler, M., Bhan, A., Kuruvilla, L., Guie, M.-A., Poffenberger, A. C., Nelson, C. D. S., Atwood, W. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302164110 · Cited by 186
Day, P. M., Gambhira, R., Roden, R. B. S., Lowy, D. R., & Schiller, J. T. (2008) · Journal of Virology · doi:10.1128/jvi.00143-08 · Cited by 183
Self-citationDeterminants of Autoantibody Induction by Conjugated Papillomavirus Virus-Like Particles
Chackerian, B., Lenz, P., Lowy, D. R., & Schiller, J. T. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.11.6120 · Cited by 181
Therapy of Human Papillomavirus-Related Disease
Stern, P. L., van der Burg, S. H., Hampson, I. N., Broker, T. R., Fiander, A., Lacey, C. J., Kitchener, H. C., & Einstein, M. H. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.05.091 · Cited by 180
Self-citationCulp, T. D., Budgeon, L. R., Marinkovich, M. P., Meneguzzi, G., & Christensen, N. D. (2006) · Journal of Virology · doi:10.1128/jvi.00724-06 · Cited by 171
In Vivo Mechanisms of Vaccine-Induced Protection against HPV Infection
Day, P. M., Kines, R. C., Thompson, C. D., Jagu, S., Roden, R. B., Lowy, D. R., & Schiller, J. T. (2010) · Cell Host & Microbe · doi:10.1016/j.chom.2010.08.003 · Cited by 171
Self-citationde Jong, A., O’Neill, T., Khan, A. Y., Kwappenberg, K. M. C., Chisholm, S. E., Whittle, N. R., Dobson, J. A., Jack, L. C., St Clair Roberts, J., Offringa, R., et al. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00350-x · Cited by 166
The biology of beta human papillomaviruses
Tommasino, M. (2016) · Virus Research · doi:10.1016/j.virusres.2016.11.013 · Cited by 166
Kitchener, H. C., Canfell, K., Gilham, C., Sargent, A., Roberts, C., Desai, M., & Peto, J. (2014) · Health Technology Assessment · doi:10.3310/hta18230 · Cited by 159
Epidemiology of oral human papillomavirus infection
Chung, C. H., Bagheri, A., & DʼSouza, G. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.09.003 · Cited by 158
Heparan Sulfate-Independent Cell Binding and Infection with Furin-Precleaved Papillomavirus Capsids
Day, P. M., Lowy, D. R., & Schiller, J. T. (2008) · Journal of Virology · doi:10.1128/jvi.01631-08 · Cited by 155
Cameron, R. L., Kavanagh, K., Pan, J., Love, J., Cuschieri, K. S., Robertson, C., Ahmed, S., Palmer, T. J., & Pollock, K. G. J. (2015) · Emerging infectious diseases · doi:10.3201/eid2201.150736 · Cited by 151
Alphs, H. H., Gambhira, R., Karanam, B., Roberts, J. N., Jagu, S., Schiller, J. T., Zeng, W., Jackson, D. C., & Roden, R. B. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800868105 · Cited by 150
Self-citationDay, P. M., Thompson, C. D., Schowalter, R. M., Lowy, D. R., & Schiller, J. T. (2013) · Journal of Virology · doi:10.1128/jvi.03222-12 · Cited by 148
Gambhira, R., Jagu, S., Karanam, B., Gravitt, P. E., Culp, T. D., Christensen, N. D., & Roden, R. B. S. (2007) · Journal of Virology · doi:10.1128/jvi.01577-07 · Cited by 143
Self-citationHuman papillomavirus in a necessary cause of invasive cervical cancer worldwide
(1999) · Pure Amsterdam UMC · doi:10.1002/(sici)1096-9896(199909)189:1 · Cited by 140
Trimble, C. L., Clark, R. A., Thoburn, C. J., Hanson, N. C., Tassello, J., Frosina, D., Kos, F. J., Teague, J. E., Jiang, Y., Barat, N. C., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002756 · Cited by 140
Deschuyteneer, M., Elouahabi, A., Plainchamp, D., et al. (2010) · Human Vaccines · doi:10.4161/hv.6.5.11023 · Cited by 132
Human Papillomavirus Type 11 Recombinant L1 Capsomeres Induce Virus-Neutralizing Antibodies
Rose, R. C., White, W. I., Li, M., Suzich, J., Lane, C., & Garcea, R. L. (1998) · Journal of Virology · doi:10.1128/jvi.72.7.6151-6154.1998 · Cited by 120
Day, P. M., Thompson, C. D., Buck, C. B., Pang, Y.-Y. S., Lowy, D. R., & Schiller, J. T. (2007) · Journal of Virology · doi:10.1128/jvi.00552-07 · Cited by 118
Longet, S., Schiller, J. T., Bobst, M., Jichlinski, P., & Nardelli‐Haefliger, D. (2011) · Journal of Virology · doi:10.1128/jvi.06093-11 · Cited by 117
Schwarz, T. F., & Léo, O. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.05.036 · Cited by 116
Richards, K. F., Bienkowska‐Haba, M., Dasgupta, J., Chen, X. S., & Sapp, M. J. (2013) · Journal of Virology · doi:10.1128/jvi.01721-13 · Cited by 111
NHPV16 VLP Vaccine Induces Human Antibodies That Neutralize Divergent Variants of HPV16
Pastrana, D. V., Vass, W. C., Lowy, D. R., & Schiller, J. T. (2001) · Virology · doi:10.1006/viro.2000.0702 · Cited by 110
Efficacy of RG1-VLP Vaccination against Infections with Genital and Cutaneous Human Papillomaviruses
Schellenbacher, C., Kwak, K., Fink, D., Shafti‐Keramat, S., Huber, B., Jindra, C., Faust, H., Dillner, J., Roden, R. B. S., & Kirnbauer, R. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.253 · Cited by 108
Self-citationFausch, S. C., Silva, D. M. D., & Kast, W. M. (2003) · PubMed · Cited by 101
Immunosuppression Facilitates the Reactivation of Latent Papillomavirus Infections
Maglennon, G. A., McIntosh, P. B., & Doorbar, J. (2013) · Journal of Virology · doi:10.1128/jvi.02589-13 · Cited by 99
Human Papillomavirus and Immunosuppression
Wieland, U., Kreuter, A., & Pfister, H. (2014) · Current problems in dermatology · doi:10.1159/000357907 · Cited by 97
Evidence and Impact of Human Papillomavirus Latency
Gravitt, P. E. (2012) · The Open Virology Journal · doi:10.2174/1874357901206010198 · Cited by 96
Dotta, L., Tassone, L., & Badolato, R. (2011) · Current Molecular Medicine · doi:10.2174/156652411795677963 · Cited by 96
Binagwaho, A., Ngabo, F., Wagner, C. M., Mugeni, C., Gatera, M., Nutt, C. T., & Nsanzimana, S. (2013) · Bulletin of the World Health Organization · doi:10.2471/blt.12.116087 · Cited by 95
Chandrachud, L. M., Grindlay, G. J., McGarvie, G. M., et al. (1995) · Virology · doi:10.1006/viro.1995.1392 · Cited by 93
Rubio, I., Seitz, H., Canali, E., Sehr, P. A., Bolchi, A., Tommasino, M., Ottonello, S., & Müller, M. (2010) · Virology · doi:10.1016/j.virol.2010.10.017 · Cited by 93
Development of AAVLP(HPV16/31L2) Particles as Broadly Protective HPV Vaccine Candidate
Nieto, K., Weghofer, M., Sehr, P. A., Ritter, M., Sedlmeier, S., Karanam, B., Seitz, H., Müller, M., Kellner, M., Hörer, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039741 · Cited by 89
Self-citationToft, L., Storgaard, M., Müller, M., Sehr, P. A., Bonde, J. H., Tolstrup, M., Østergaard, L. J., & Søgaard, O. S. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit657 · Cited by 88
Lowy, D. R., Herrero, R., & Hildesheim, A. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70075-6 · Cited by 85
Herrin, D., Coates, E. E., Costner, P. J. M., Kemp, T. J., Nason, M., Saharia, K., Pan, Y., Sarwar, U. N., Holman, L. A., Yamshchikov, G. V., et al. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.34408 · Cited by 80
Cryoelectron Microscopy Maps of Human Papillomavirus 16 Reveal L2 Densities and Heparin Binding Site
Guan, J., Bywaters, S. M., Brendle, S. A., Ashley, R. E., Makhov, A. M., Conway, J. F., Christensen, N. D., & Hafenstein, S. L. (2017) · Structure · doi:10.1016/j.str.2016.12.001 · Cited by 79
Lehtinen, M., Söderlund‐Strand, A., Vänskä, S., Luostarinen, T., Eriksson, T., Natunen, K., Apter, D. L., Baussano, I., Harjula, K., Hokkanen, M., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.31119 · Cited by 79
Elfström, K. M., Lazzarato, F., Franceschi, S., Dillner, J., & Baussano, I. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv368 · Cited by 76
Scherpenisse, M., Schepp, R. M., Mollers, M., Meijer, C. J. L. M., Berbers, G. A. M., & van der Klis, F. R. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074797 · Cited by 76
Tumban, E., Peabody, J., Peabody, D. S., & Chackerian, B. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.07.052 · Cited by 74
Introduction of a National HPV vaccination program into Bhutan
Dorji, T., Tshomo, U., Phuntsho, S., Tamang, T. D., Tshokey, T., Baussano, I., Franceschi, S., & Clifford, G. M. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.05.078 · Cited by 71
Geraets, D. T., Alemany, L., Guimerà, N., de Sanjosé, S., de Koning, M. N. C., Molijn, A. C., Jenkins, D., Bosch, F. X., Quint, W. G. V., & on behalf of the RIS HPV TT Study Group (2012) · The Journal of Pathology · doi:10.1002/path.4065 · Cited by 70
Giacomet, V., Penagini, F., Trabattoni, D., et al. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.08.011 · Cited by 69
Scherer, E. M., Smith, R. A. J., Simonich, C. A. L., Niyonzima, N., Carter, J. J., & Galloway, D. A. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004461 · Cited by 68
Manufacturing costs of HPV vaccines for developing countries
Clendinen, C., Zhang, Y., Warburton, R., & Light, D. W. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.09.042 · Cited by 68
Cruising the cellular highways: how human papillomavirus travels from the surface to the nucleus
DiGiuseppe, S., Bienkowska-Haba, M., Guion, L. G., & Sapp, M. (2017) · Virus Research · doi:10.1016/j.virusres.2016.10.015 · Cited by 67
Palmer, T. J., McFadden, M., Pollock, K. G. J., Kavanagh, K., Cuschieri, K. S., Cruickshank, M. E., Cotton, S. C., Nicoll, S., & Robertson, C. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.474 · Cited by 64
Immunologic Control of Mus musculus Papillomavirus Type 1
Wang, J. W., Jiang, R. T., Peng, S., Chang, Y.-N., Hung, C., & Roden, R. B. S. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1005243 · Cited by 57
Self-citationReactivation of Latent HPV Infections After Renal Transplantation
Hinten, F., Hilbrands, L. B., Meeuwis, K. A. P., IntHout, J., Quint, W. G. V., Hoitsma, A. J., Massuger, L. F. A. G., Melchers, W. J. G., & de Hullu, J. A. (2016) · American Journal of Transplantation · doi:10.1111/ajt.14181 · Cited by 57
Human papillomavirus-driven immune deviation: challenge and novel opportunity for immunotherapy
Smola, S., Trimble, C., & Stern, P. L. (2017) · Therapeutic Advances in Vaccines · doi:10.1177/2051013617717914 · Cited by 57
Self-citationKemp, T. J., Safaeian, M., Hildesheim, A., Pan, Y., Penrose, K. J., Porras, C., Schiller, J. T., Lowy, D. R., Herrero, R., & Pinto, L. A. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.067 · Cited by 55
Canvin, M., Sinka, K., Hughes, G., & Mesher, D. (2016) · Sexually Transmitted Infections · doi:10.1136/sextrans-2016-052626 · Cited by 53
Development of a highly thermostable, adjuvanted human papillomavirus vaccine
Hassett, K. J., Meinerz, N. M., Semmelmann, F., Cousins, M. C., Garcea, R. L., & Randolph, T. W. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.05.009 · Cited by 52
Leung, T. F., Liu, A. P. Y., Lim, F. S., Thollot, F., Oh, H. M. L., Lee, B. W., Rombo, L., Tan, N. C., Rouzier, R., Friel, D., et al. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1050570 · Cited by 52
Matsui, K., Adelsberger, J. W., Kemp, T. J., Baseler, M., Ledgerwood, J. E., & Pinto, L. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137195 · Cited by 52
Schwarz, T. F., Kocken, M., Petäjä, T., Einstein, M. H., Spaczyński, M., Louwers, J. A., Pedersen, C., Levin, M. J., Zahaf, T., Poncelet, S. M., et al. (2010) · Human Vaccines · doi:10.4161/hv.6.12.13399 · Cited by 51
Kreimer, A. R., Sherman, M. E., Sahasrabuddhe, V. V., & Safaeian, M. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju436 · Cited by 51
van Esch, E. M. G., van Poelgeest, M. I. E., Trimbos, J. B., Fleuren, G. J., Jordanova, E. S., & van der Burg, S. H. (2014) · International Journal of Cancer · doi:10.1002/ijc.29173 · Cited by 50
Kwak, K., Jiang, R. T., Wang, J. W., Jagu, S., Kirnbauer, R., & Roden, R. B. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097232 · Cited by 50
Self-citationImpact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis
Cuschieri, K. S., Kavanagh, K., Moore, C., Bhatia, R., Love, J., & Pollock, K. G. J. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.97 · Cited by 47
Cruz, L., & Meyers, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068379 · Cited by 41
Wang, J. W., Jagu, S., Kwak, K., Wang, C., Peng, S., Kirnbauer, R., & Roden, R. B. S. (2013) · Virology · doi:10.1016/j.virol.2013.10.038 · Cited by 39
Self-citationCross-Neutralization Potential of Native Human Papillomavirus N-Terminal L2 Epitopes
Conway, M. J., Cruz, L., Alam, S., Christensen, N. D., & Meyers, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016405 · Cited by 37
Interferon Gamma Prevents Infectious Entry of Human Papillomavirus 16 via an L2-Dependent Mechanism
Day, P. M., Thompson, C. D., Lowy, D. R., & Schiller, J. T. (2017) · Journal of Virology · doi:10.1128/jvi.00168-17 · Cited by 37
Conway, M. J., Cruz, L., Alam, S., Christensen, N. D., & Meyers, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022427 · Cited by 35
Incoming human papillomavirus 16 genome is lost in PML protein-deficient HaCaT keratinocytes
Bienkowska‐Haba, M., Łuszczek, W., Keiffer, T. R., Guion, L. G. M., DiGiuseppe, S., Scott, R. S., & Sapp, M. J. (2016) · Cellular Microbiology · doi:10.1111/cmi.12708 · Cited by 32
Impact of Human Papillomavirus Vaccination on Cervical Cytology Screening, Colposcopy, and Treatment
Rodríguez, A. C., Solomon, D., Herrero, R., Hildesheim, A., González, P., Wacholder, S., Porras, C., Jiménez, S., SCHIFFMAN, M. H., & for the CVT Group (2013) · American Journal of Epidemiology · doi:10.1093/aje/kwt047 · Cited by 30
Kalnin, K. V., Chivukula, S. V., Tibbitts, T. J., Yan, Y., Stegalkina, S. S., Shen, L., Cieszynski, J., Costa, V., Sabharwal, R., Anderson, S. F., et al. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.07.086 · Cited by 29
Self-citationvan Esch, E. M. G., van Poelgeest, M. I. E., Kouwenberg, S., Osse, E. M., Trimbos, J. B., Fleuren, G. J., Jordanova, E. S., & van der Burg, S. H. (2014) · International Journal of Cancer · doi:10.1002/ijc.29174 · Cited by 28
Huang, L., Puthanakit, T., Cheng-Hsun, C., Tang, R.-B., Schwarz, T. F., Pellegrino, A., Esposito, S., Frenette, L., McNeil, S., Durando, P., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix154 · Cited by 27
Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs
Senger, T., Schädlich, L., Textor, S., Klein, C., Michael, K. M., Buck, C. B., & Gissmann, L. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.11.048 · Cited by 25
Human papillomavirus vaccination at a time of changing sexual behavior
Baussano, I., Lazzarato, F., Brisson, M., & Franceschi, S. (2016) · Emerging Infectious Diseases · doi:10.3201/eid2201.150791 · Cited by 24
Heeren, A. M., Kenter, G. G., Jordanova, E. S., & de Gruijl, T. D. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1009296 · Cited by 24
Wang, J. W., Jagu, S., Wu, W.-H., Viscidi, R. P., Macgregor-Das, A. M., Fogel, J. M., Kwak, K., Daayana, S., Kitchener, H. C., Stern, P. L., et al. (2015) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00799-14 · Cited by 24
Self-citationEffect of Different Human Papillomavirus Serological and DNA Criteria on Vaccine Efficacy Estimates
Kuhs, K. A. L., Porras, C., Schiller, J. T., Rodríguez, A. C., SCHIFFMAN, M. H., González, P., Wacholder, S., Ghosh, A., Li, Y., Lowy, D. R., et al. (2014) · American Journal of Epidemiology · doi:10.1093/aje/kwu168 · Cited by 21
Barroeta, J. E., Adhikari‐Guragain, D., & Grotkowski, C. E. (2017) · Diagnostic Cytopathology · doi:10.1002/dc.23737 · Cited by 16
Cited by
Turning the corner on therapeutic cancer vaccines
Hollingsworth, R. E., & Jansen, K. (2019) · npj Vaccines · doi:10.1038/s41541-019-0103-y · Cited by 689
Human papillomaviruses: diversity, infection and host interactions
McBride, A. A. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00617-5 · Cited by 369
Human Papillomavirus Vaccines: An Updated Review
Cheng, L., Wang, Y., & Du, J. (2020) · Vaccines · doi:10.3390/vaccines8030391 · Cited by 329
Regulatory mechanisms of one-carbon metabolism enzymes
Petrova, B., Maynard, A. G., Wang, P., & Kanarek, N. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105457 · Cited by 103
Engineering virus resistance via CRISPR–Cas systems
Mahas, A., & Mahfouz, M. (2018) · Current Opinion in Virology · doi:10.1016/j.coviro.2018.06.002 · Cited by 74
Metadata
- Authors
- Roden, R. B. S., & Stern, P. L.
- Venue
- Nature Reviews Cancer
- Published
- 2018-03-02
- Volume
- 18
- Issue
- 4
- Pages
- 240-254
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2792074753
- Cited by
- 333
- References
- 138
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.